Viral rebound common in lung transplant recipients treated with nirmatrelvir/ritonavir for COVID-19 Post author: Post published:October 24, 2023 Post category:uncategorized Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. You Might Also Like Medicare Advantage is popular, but some beneficiaries feel buyer’s remorse January 23, 2024 High sugary beverage consumption during pregnancy linked to increased health risks July 30, 2024 AI detects colorectal cancer with high accuracy February 28, 2025